Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Stephan Kruck; Markus A. Kuczyk; Georgios Gakis; Mario W. Kramer; Arnulf Stenzl; Axel S. Merseburger

doi:10.2174/157488708785700311

Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Stephan Kruck, Markus A. Kuczyk^*, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl, Axel S. Merseburger

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Urologie

9 Zitate (Scopus)

Abstract

Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies" particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

Originalsprache	Englisch
Zeitschrift	Reviews on Recent Clinical Trials
Jahrgang	3
Ausgabenummer	3
Seiten (von - bis)	212-216
Seitenumfang	5
ISSN	1574-8871
DOIs	https://doi.org/10.2174/157488708785700311
Publikationsstatus	Veröffentlicht - 09.2008

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

Dokumente

10.2174/157488708785700311

Weitere Links

Link to publication in Scopus

Zitieren

@article{e7bee6dc70d149aa90ce2d54ced12dc4,

title = "Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update",

abstract = "Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the {"}targeted therapies{"} particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.",

author = "Stephan Kruck and Kuczyk, \{Markus A.\} and Georgios Gakis and Kramer, \{Mario W.\} and Arnulf Stenzl and Merseburger, \{Axel S.\}",

year = "2008",

month = sep,

doi = "10.2174/157488708785700311",

language = "English",

volume = "3",

pages = "212--216",

journal = "Reviews on Recent Clinical Trials",

issn = "1574-8871",

publisher = "Bentham Science Publishers",

number = "3",

}

TY - JOUR

T1 - Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

AU - Kruck, Stephan

AU - Kuczyk, Markus A.

AU - Gakis, Georgios

AU - Kramer, Mario W.

AU - Stenzl, Arnulf

AU - Merseburger, Axel S.

PY - 2008/9

Y1 - 2008/9

N2 - Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies" particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

AB - Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies" particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

UR - https://www.scopus.com/pages/publications/54049131744

U2 - 10.2174/157488708785700311

DO - 10.2174/157488708785700311

M3 - Scientific review articles

C2 - 18782079

AN - SCOPUS:54049131744

SN - 1574-8871

VL - 3

SP - 212

EP - 216

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

IS - 3

ER -

Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Abstract

UN SDGs

Strategische Forschungsbereiche und Zentren

Dokumente

Weitere Links

Fingerprint

Zitieren